INmune Bio, Inc. (NASDAQ: INMB) today announced a
poster presentation related to its program in Alzheimer’s disease at the
upcoming Society for Neuroscience (“SfN”) 49th Annual Meeting to be held at
McCormick Place in Chicago from Oct. 19–23, 2019. The company also announced
that its poster was selected for presentation during the meeting’s press
conference. The data from studies involving the use of INmune Bio’s XPro1595,
as presented in a poster by Malú Tansey, Ph.D., Professor of Neuroscience and
Director of the Center for Translational Research in Neurodegenerative Disease
at the University of Florida College of Medicine, demonstrate the critical role
of the immune system on an individual’s genetic risk in the context of
environmental exposures, such as a diet high in fat and sugar, for
neurodegenerative diseases such as Alzheimer’s. “It’s become clear that
neurological disorders can arise from or be exacerbated by innate immune
dysfunction and chronic inflammation resulting from both genetic and
environmental factors such as diet,” Dr. Tansey said in the news release.
“Harnessing the power of the immune system could potentially delay or perhaps
even prevent some of these neurological disorders. Our results provide a
compelling rationale for moving forward with a clinical trial in early Alzheimer’s
disease patients.”
To view the full press release, visit http://ibn.fm/PWOZt
About INmune Bio, Inc.
INmune Bio, Inc. is a publicly traded, clinical-stage
biotechnology company developing therapies targeting the innate immune system
to fight disease. INmune Bio is developing three product platforms: two
products that reengineer the patient’s innate immune system’s response to
cancer and one product to treat neuroinflammation that is currently focused on
Alzheimer’s disease. INKmune is a natural killer (“NK”) cell therapeutic that
primes the patient’s NK cells to attack minimal residual disease, the remaining
cancer cells that are difficult to detect, which often cause relapse. INB03
inhibits myeloid-derived suppressor cells (“MDSC”), which often cause
resistance to immunotherapy, such as anti-PD-1 checkpoint inhibitors. XPro1595
targets neuroinflammation, which causes microglial activation and neuronal cell
death. INmune Bio’s product platforms utilize a precision medicine approach for
the treatment of a wide variety of hematologic malignancies, solid tumors and
chronic inflammation. For more information, visit the company’s website
at www.INmuneBio.com.
NOTE TO INVESTORS: The latest news and updates
relating to INMB are available in the company’s newsroom at http://ibn.fm/INMB
About MissionIRNewsBreaks
MissionIRNewsBreaks provide
a rapid summary of corporate news that catch the attention of MissionIR. MissionIRNewsBreaks are created by
our Team of professional journalists that keep a constant eye on the markets,
these posts are designed to inform you on the latest happenings of our clients
and other publicly traded companies on our radar. From earnings, acquisitions
and agreements to conference attendance and clinical study results, our news breaks
keep you up-to-date with the day’s top movers. MissionIR is primarily focused
on strategic communications. We have executed countless communications programs
to address the needs of companies ranging from start-ups to established
industry leaders, gaining valuable experience and the expertise necessary to
determine the most effective strategy for any given situation.
Please see full terms of use and disclaimers on the Mission
Investor Relations website applicable to all content provided by MIR, wherever
published or re-published: http://www.missionir.com/disclaimer.html
